Wang 2015b.

Methods	Study design: Randomised clinical trial Study duration: January 2011 to September 2014 Duration of follow‐up: 6 months Setting: Hospital
Participants	Inclusion criteria: Diagnosed as HCC by images and pathology Exclusion criteria: Abnormal haematopoietic and immune function; with other tumours Age (mean ± SD): TACE + RFA: 58.6 ± 6.2 years; TACE alone: 58.3 ± 6.5 years Male (n/total): TACE + RFA: 32/50; TACE alone: 31/50 Tumour diameter (mean ± SD): TACE + RFA: 5.1 ± 1.2 cm, TACE: 5.0 ± 1.3 cm TNM stage (patients): StageⅠ: TACE + RFA: 13; TACE: 13 StageⅡ: TACE + RFA: 31; TACE: 30 StageⅢ: TACE + RFA: 6; TACE: 7 Child‐Pugh Class (patients): Class A: TACE + RFA: 36; TACE: 35 Class B: TACE + RFA: 14; TACE: 15
Interventions	TACE + RFA group (n = 50): TACE: Chemotherapeutic drugs: 5‐fluorouracil 2 g and oxaliplatin 200 mg RFA: The interval between TACE and RFA was 2 weeks. Output power of 60 W, ablation margin of 1 cm TACE group (n = 50): Chemotherapeutic drugs: 5‐fluorouracil 2 g and oxaliplatin 200 mg
Outcomes	Tumour response, classified as complete response, partial response, stable disease, and progression 6‐month survival rate 6‐month recurrence rate Adverse events
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.